Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Bifidobacterium infantis is supported by scientific evidence for use in colitis, particularly for ulcerative colitis and, to a lesser extent, other forms of inflammatory bowel disease (IBD). Several clinical trials and preclinical studies have investigated its impact on gut inflammation and mucosal health. B. infantis is known to modulate the gut microbiota, enhance the integrity of the intestinal barrier, and regulate the immune response. Research, including randomized controlled trials, has shown that supplementation with B. infantis can reduce inflammatory markers (such as TNF-α and IL-6), decrease symptoms, and improve quality of life in some patients with ulcerative colitis. The proposed mechanisms include competitive inhibition of pathogenic bacteria, production of anti-inflammatory metabolites (like short-chain fatty acids), and modulation of T-regulatory cell activity.

However, the overall evidence base is still moderate rather than robust. Some studies have demonstrated statistically significant benefits, while others have reported only marginal or non-significant improvements. Meta-analyses suggest a possible adjunctive role for B. infantis (often in combination with other probiotics), but it is not universally recommended as a primary therapy for colitis. The safety profile is generally favorable, with few adverse events reported. Further large-scale, well-designed trials are needed to definitively establish efficacy and optimize dosing strategies for different types of colitis.

More about Bifidobacterium infantis
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Bifidobacterium infantis

Products containing Bifidobacterium infantis

Nature's Sunshine Eleven Elevated (NutriBiome)
Nature's Sunshine Probiotic Eleven
Nature's Sunshine Sunshine Heroes Probiotic Power